We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Novel Method Detects Kidney Cancer Biomarkers in Urine

By LabMedica International staff writers
Posted on 24 Dec 2012
A rapid and inexpensive method using bioplasmonic paper was developed for detecting biomarkers of kidney cancer in urine.

Two biomarkers are present in elevated amounts in the urine of patients with kidney cancer, aquaporin-1 and adipophilin. More...
A team of scientists created what they call bioplasmonic paper—filter paper impregnated with gold nanorods linked to antibodies that would bind to aquaporin-1. Gold nanorods respond to light by producing localized surface plasmon resonance (LSPR), a specific type of light emission that involves waves of electrons moving across the surface of metal nanostructures. LSPR is very sensitive to molecular events that occur on or near the surface of the particles, including binding of bimolecules to attached antibodies.

Traditionally, LSPR detection devices are rigid, flat surfaces such as glass, but Dr. Srikanth Singamaneni from the department of mechanical engineering and the Siteman Cancer Center at Washington University (St Louis, MO, USA) and colleagues demonstrated that standard filter paper can also serve as an LSPR substrate. The team found that the sensitivity and limit of detection for the paper-based system is at least as good, if not better, than for conventional rigid substrates. In this case, the limit of detection matched that of the range of aquaporin-1 levels in patients with kidney cancer. Other advantages of using paper include its wicking properties, flexible surface for collection, compatibility with standard ink jet printing technology, low cost, and ease of disposal.

The findings were published online on October 25, 2012, in the journal Analytical Chemistry.

Currently, the technology used clinically to detect specific proteins such as the two kidney cancer biomarkers, known as an enzyme-linked immunosorbent assay (ELISA), is both expensive and time-consuming, and requires a relatively high level of laboratory expertise to produce accurate results.

Related Links:

Washington University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.